p53 mutations as fingerprints for aristolochic acid - an environmental carcinogen in endemic (Balkan) nephropathy

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 663, Issue 1-2, 2009, Pages 1-6

  Slade, Neda ^a   Moll, Ute M ^b   Brdar, Branko ^a   Zorić, Arijana ^a   Jelaković, Bojan ^c  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b STONY BROOK UNIVERSITY   (United States)

^c KBC Zagreb   (Croatia)

Author keywords

Aristolochic acid; Aristolochic acid nephropathy; DNA adducts; Endemic nephropathy; Environmental carcinogen; p53 mutations

Indexed keywords

ARISTOLOCHIC ACID; PROTEIN P53;

ARISTOLOCHIA; CARCINOGENESIS; DNA ADDUCT; DNA MICROARRAY; GENE MUTATION; INTERSTITIAL NEPHRITIS; KIDNEY CORTEX; KIDNEY FAILURE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; UROGENITAL TRACT CANCER;

ARISTOLOCHIC ACIDS; BALKAN NEPHROPATHY; CARCINOGENS, ENVIRONMENTAL; HUMANS; MUTAGENS; MUTATION; TUMOR SUPPRESSOR PROTEIN P53;

ARISTOLOCHIA; RATTUS;

EID: 63549124370     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2009.01.005     Document Type: Short Survey

References (68)

1. Yuspa S.H., and Poirier M.C. Chemical carcinogenesis: from animal models to molecular models in one decade. Adv. Cancer Res. 50 (1988) 25-70
2. Vogelstein B., and Kinzler K.W. Carcinogens leave fingerprints. Nature 355 (1992) 209-210
3. Greenblatt M.S., Bennett W.P., Hollstein M., and Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54 (1994) 4855-4878
4. Hollstein M., Moeckel G., Hergenhahn M., Spiegelhalder B., Keil M., Werle-Schneider G., Bartsch H., and Brickmann J. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat. Res. 405 (1998) 145-154
5. Petitjean A., Mathe E., Kato S., Ishioka C., Tavtigian S.V., Hainaut P., and Olivier M. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum. Mutat. 28 (2007) 622-629
6. Slade N., and Moll U.M. Mutational analysis of p53 in human tumors: immunocytochemistry. Methods Mol. Biol. 234 (2003) 231-243
7. Erster S., Slade N., and Moll U.M. Mutational analysis of p53 in human tumors: direct DNA sequencing and SSCP. Methods Mol. Biol. 234 (2003) 219-230
8. Hussain S.P., Hollstein M.H., and Harris C.C. p53 tumor suppressor gene: at the crossroads of molecular carcinogenesis, molecular epidemiology, and human risk assessment. Ann. N.Y. Acad. Sci. 919 (2000) 79-85
9. Denissenko M.F., Pao A., Tang M., and Pfeifer G.P. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in p53. Science 274 (1996) 430-432
10. Li D., Cao Y., He L., Wang N.J., and Gu J.R. Aberrations of p53 gene in human hepatocellular carcinoma from China. Carcinogenesis 14 (1993) 169-173
11. Soini Y., Chia S.C., Bennett W.P., Groopman J.D., Wang J.S., DeBenedetti V.M., Cawley H., Welsh J.A., Hansen C., Bergasa N.V., Jones E.A., DiBisceglie A.M., Trivers G.E., Sandoval C.A., Calderon I.E., Munoz Espinosa L.E., and Harris C.C. An aflatoxin-associated mutational hotspot at codon 249 in the p53 tumor suppressor gene occurs in hepatocellular carcinomas from Mexico. Carcinogenesis 17 (1996) 1007-1012
12. Hsu I.C., Metcalf R.A., Sun T., Welsh J.A., Wang N.J., and Harris C.C. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 350 (1991) 427-428
13. Forrester K., Lupold S.E., Ott V.L., Chay C.H., Band V., Wang X.W., and Harris C.C. Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. Oncogene 10 (1995) 2103-2111
14. Ziegler A., Jonason A.S., Leffell D.J., Simon J.A., Sharma H.W., Kimmelman J.J., Remington L., Jacks T., and Brash D.E. Sunburn and p53 in the onset of skin cancer. Nature 372 (1994) 773-776
15. Vähäkangas K.H., Samet J.M., Metcalf R.A., Welsh J.A., Bennett W.P., Lane D.P., and Harris C.C. Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 339 (1992) 576-580
16. Hollstein M., Marion M.J., Lehman T., Welsh J., Harris C.C., Martel-Planche G., Kusters I., and Montesano R. p53 mutations at A:T base pairs in angiosarcomas of vinyl chloride-exposed factory workers. Carcinogenesis 15 (1994) 1-3
17. Hussain S.P., Hofseth L.J., and Harris C.C. Tumor suppressor genes: at the crossroads of molecular carcinogenesis, molecular epidemiology and human risk assessment. Lung Cancer 34 (2001) 7-15
18. Dawson W.R. Birthwort: a study of the progress of medical botany through twenty-two centuries. Pharm. J. Pharmacist. (1927) 396-430
19. Mengs U., Lang W., and Poch J.A. The carcinogenic action of aristolochic acid in rats. Arch. Toxicol. 51 (1982) 107-119
20. Robisch G., Schimmer O., and Goggelmann W. Aristolochic acid is a direct mutagen in Salmonella typhimurium. Mutat. Res. 105 (1982) 201-204
21. Schmeiser H.H., Pool B.L., and Wiessler M. Mutagenicity of the two main components of commercially available carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett. 23 (1984) 97-101
22. Schmeiser H.H., Pool B.L., and Wiessler M. Identification and mutagenicity of metabolites of aristolochic acid formed by rat liver. Carcinogenesis 7 (1986) 59-63
23. Xiao Y., Ge M., Xue X., Wang C., Wang H., Wu X., Li L., Liu L., Qi X., Zhang Y., Li Y., Luo H., Xie T., Gu J., and Ren J. Hepatic cytochrome P450s metabolize aristolochic acid and reduce its kidney toxicity. Kidney Int. 73 (2008) 1231-1239
24. Stiborová M., Frei E., Hodek P., Wiessler M., and Schmeiser H.H. Human hepatic and renal microsomes, cytochromes P450 1A1/2 NADPH:cytochrome P450 reductase and prostaglandin H synthase mediate the formation of aristolochic acid-DNA adducts found in patients with urothelial cancer. Int. J. Cancer 113 (2005) 189-197
25. Shibutani S., Dong H., Suzuki N., Ueda S., Miller F., and Grollman A.P. Selective toxicity of aristolochic acids I and II. Drug Metab. Dispos. 35 (2007) 1217-1222
26. Stiborová M., Frei E., and Schmeiser H.H. Biotransformation enzymes in development of renal injury and urothelial cancer caused by aristolochic acid. Kidney Int. 73 (2008) 1209-1211
27. Stiborová M., Frei E., Arlt V.M., and Schmeiser H.H. Metabolic activation of carcinogenic aristolochic acid, a risk factor for Balkan endemic nephropathy. Mutat. Res. 658 (2008) 55-67
28. Mei N., Arlt V.M., Phillips D.H., Heflich R.H., and Chen T. DNA adduct formation and mutation induction by aristolochic acid in rat kidney and liver. Mutat. Res. 602 (2006) 83-91
29. Cosyns J.P. Aristolochic acid and Chinese herbs nephropathy: a review of the evidence to date. Drug Saf. 26 (2003) 33-48
30. Cosyns J.P., Jadoul M., Squifflet J.P., De Plaen J.F., Ferluga D., and van Ypersele de Strihou C. Chinese herbs nephropathy: a clue to Balkan endemic nephropathy?. Kidney Int. 45 (1994) 1680-1688
31. Kozlowski J.M., and Smith N. Cancer of the Bladder. In: Saclarides T.J., Millikan K.W., and Godellas C.V. (Eds). Surgical Oncology: An Algorithmic Approach (2003), Springer, New York pp.440-451
32. Nortier J. Renal interstitial fibrosis and urotelial carcinomas after ingestion of a Chinese herb (Aristolochia fangchi). Nephrologie 23 (2002) 37-38
33. Vanhaelen M., Vanhaelen-Fastre R., But P., and Vanherweghem J.L. Identification of aristolochic acid in Chinese herbs. Lancet 343 (1994) 174
34. Cosyns J.P., Jadoul M., Squifflet J.P., Wese F.X., and van Ypersele de Strihou C. Urothelial lesions in Chinese-herb nephropathy. Am. J. Kidney Dis. 33 (1999) 1011-1017
35. Cosyns J.P., Jadoul M., Squifflet J.P., Van Cangh P.J., and van Ypersele de Strihou C. Urothelial malignancy in nephropathy due to Chinese herbs. Lancet 344 (1994) 188
36. Nortier J.L., Martinez M.C., Schmeiser H.H., Arlt V.M., Bieler C.A., Petein M., Depierreux M.F., De Pauw L., Abramowicz D., Vereerstraeten P., and Vanherweghem J.L. Urothelial carcinoma associated with the use of a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 342 (2000) 1686-1692
37. Genega E.M., and Porter C.R. Urothelial neoplasms of the kidney and ureter. An epidemiologic, pathologic, and clinical review. Am. J. Clin. Pathol. 117 (2002) S36-48
38. Lemy A., Wissing K.M., Rorive S., Zlotta A., Roumeguere T., Muniz Martinez M.C., Decaestecker C., Salmon I., Abramowicz D., Vanherweghem J.L., and Nortier J. Late onset of bladder urothelial carcinoma after kidney transplantation for end-stage aristolochic acid nephropathy: a case series with 15-year follow-up. Am. J. Kidney Dis. 51 (2008) 471-477
39. Arlt V.M., Stiborová M., and Schmeiser H.H. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 17 (2002) 265-277
40. Schmeiser H.H., Schoepe K.B., and Wiessler M. DNA adduct formation of aristolochic acid I and II in vitro and in vivo. Carcinogenesis 9 (1988) 297-303
41. Pfau W., Schmeiser H.H., and Wiessler M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 11 (1990) 313-319
42. Stiborová M., Fernando R.C., Schmeiser H.H., Frei E., Pfau W., and Wiessler M. Characterization of DNA adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 15 (1994) 1187-1192
43. 32P-post-labelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese herbs nephropathy. Carcinogenesis 18 (1997) 1063-1067
44. Grollman A.P., Shibutani S., Moriya M., Miller F., Wu L., Moll U.M., Suzuki N., Fernandes A., Rosenquist T., Medverec Z., Jakovina K., Brdar B., Slade N., Turesky R.J., Goodenough A.K., Rieger R., Vukelić M., and Jelaković B. Aristolochic acid and the etiology of endemic (Balkan) nephropathy. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 12129-12134
45. Arlt V.M., Stiborová M., vom Brocke J., Simões M.L., Lord G.M., Nortier J.L., Hollstein M., Phillips D.H., and Schmeiser H.H. Aristolochic acid mutagenesis: molecular clues to the aetiology of Balkan endemic nephropathy-associated urothelial cancer. Carcinogenesis 28 (2007) 253-261
46. Schmeiser H.H., Bieler C.A., Wiessler M., van Ypersele de Strihou C., and Cosyns J.P. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res. 56 (1996) 2025-2028
47. Schmeiser H.H., Janssen J.W., Lyons J., Scherf H.R., Pfau W., Buchmann A., Bartram C.R., and Wiessler M. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res. 50 (1990) 5464-5469
48. Schmeiser H.H., Scherf H.R., and Wiessler M. Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett. 59 (1991) 139-143
49. Liu Z., Hergenhahn M., Schmeiser H.H., Wogan G.N., Hong A., and Hollstein M. Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 2963-2968
50. Lord G.M., Hollstein M., Arlt V.M., Roufosse C., Pusey C.D., Cook T., and Schmeiser H.H. DNA adducts and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 43 (2004) e11-17
51. Feldmeyer N., Schmeiser H.H., Muehlbauer K.R., Belharazem D., Knyazev Y., Nedelko T., and Hollstein M. Further studies with a cell immortalization assay to investigate the mutation signature of aristolochic acid in human p53 sequences. Mutat. Res. 608 (2006) 163-168
52. Arlt V.M., Schmeiser H.H., and Pfeifer G.P. Sequence-specific detection of aristolochic acid-DNA adducts in the human p53 gene by terminal transferase-dependent PCR. Carcinogenesis 22 (2001) 133-140
53. Chen L., Mei N., Yao L., and Chen T. Mutations induced by carcinogenic doses of aristolochic acid in kidney of Big Blue transgenic rats. Toxicol. Lett. 165 (2006) 250-256
54. Miletić-Medved M., Jelaković B., Bistrović D., Leko N., and Marić Z. Epidemiologic characteristics of endemic nephropathy in Croatia in 2005. Acta Med. Croatica 61 (2007) 141-148
55. Bukvić D., Marić I., Arsenović A., Janković S., and Djukanović L. Prevalence of Balkan endemic nephropathy has not changed since 1971 in the Kolubara region in Serbia. Kidney Blood Press Res. 30 (2007) 117-123
56. Miletić-Medved M., Domijan A.M., and Peraica M. Recent data on endemic nephropathy and related urothelial tumors in Croatia. Wien. Klin. Wochenschr. 117 (2005) 604-609
57. Voice T.C., Long D.T., Radovanović Z., Atkins J.L., McElmurry S.P., Niagolova N.D., Dimitrov P., Petropoulos E.A., and Ganev V.S. Critical evaluation of environmental exposure agents suspected in the etiology of Balkan endemic nephropathy. Int. J. Occup. Environ. Health 12 (2006) 369-376
58. Pfohl-Leszkowicz A., Grosse Y., Castegnaro M., Nicolov I.G., Chernozemsky I.N., Bartsch H., Betbeder A.M., Creppy E.E., and Dirheimer G. Ochratoxin A-related DNA adducts in urinary tract tumours of Bulgarian subjects. IARC Sci. Publ. 124 (1993) 141-148
59. Mally A., Hard G.C., and Dekant W. Ochratoxin A as a potential etiologic factor in endemic nephropathy: lessons from toxicity studies in rats. Food Chem. Toxicol. 45 (2007) 2254-2260
60. Cavin C., Delatour T., Marin-Kuan M., Holzhäuser D., Higgins L., Bezençon C., Guignard G., Junod S., Richoz-Payot J., Gremaud E., Hayes J.D., Nestler S., Mantle P., and Schilter B. Reduction in antioxidant defenses may contribute to ochratoxin A toxicity and carcinogenicity. Toxicol. Sci. 96 (2007) 30-39
61. Arlt V.M., Ferluga D., Stiborová M., Pfohl-Leszkowicz A., Vukelić M., Čeović S., Schmeiser H.H., and Cosyns J.P. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer?. Int. J. Cancer 101 (2002) 500-502
62. Grollman A.P., and Jelaković B. Role of environmental toxins in endemic (Balkan) nephropathy. J. Am. Soc. Nephrol. 18 (2007) 2817-2823
63. Fink-Gremmels J. Conclusion from the workshops on ochratoxin A in food: Recent developments and significance, organized by ILSI Europe in Baden (Austria) 29 June-1 July 2005. Food Addit. Contam. 22 (2005) S11-5
64. EFSA (European Food Safety Authority) Scientific Panel on Contaminants in the Food Chain. Opinion of the scientific panel on contaminants in the food chain on a request from the commission related to ochratoxin A in food. EFSA J. 365 (2006) 1-56.
65. Ivić M. Etiology of endemic nephropathy. Liječ Vjesn. 91 (1969) 1273-1281
66. Hranjec T., Kovač A., Kos J., Mao W., Chen J.J., Grollman A.P., and Jelaković B. Endemic nephropathy: the case for chronic poisoning by Aristolochia. Croat. Med. J. 46 (2005) 116-125
67. Fištrek M., Kovač-Peić A., Kos J., Pećin I., Barišić M., Hadžibegić I., D{combining short stroke overlay}anić A., Mišić M., Dika Z., Miletić-Medved M., Cvitković A., Bistrović D., Grollman A.P., and Jelaković B. Ingestion of herbal teas in Croatian endemic area. Acta Med. Croat. 62 (2008) S110
68. Debelle F., Vanherweghem J.-L., and Nortier J. Aristolochic acid nephropathy: a worldwide problem. Kidney Int. 74 (2008) 158-169